Novo Nordisk A/S (NYSE:NVO) is Vantage Investment Partners LLC’s 4th Largest Position

Vantage Investment Partners LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 35.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 580,417 shares of the company’s stock after buying an additional 151,620 shares during the quarter. Novo Nordisk A/S comprises 4.4% of Vantage Investment Partners LLC’s portfolio, making the stock its 4th largest position. Vantage Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $49,927,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Raymond James & Associates lifted its stake in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after purchasing an additional 36,223 shares during the period. Natixis Advisors LLC increased its stake in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares in the last quarter. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the period. LPL Financial LLC boosted its stake in Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock worth $162,266,000 after acquiring an additional 47,496 shares in the last quarter. Finally, Mediolanum International Funds Ltd purchased a new stake in Novo Nordisk A/S in the third quarter worth about $98,765,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $87.45 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market capitalization of $392.43 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 0.90 and a beta of 0.45. The stock has a 50-day moving average of $95.35 and a 200 day moving average of $114.80. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.